×

Do you want to link to this External Website and leave Amgen.nl?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Netherlands takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Wilt u deze Externe Website bezoeken en Amgen.nl verlaten?

U verlaat nu de website van Amgen Nederland. Amgen Nederland draagt geen verantwoordelijkheid voor, en oefent geen controle uit, over de organisaties, meningen or juistheid van de informatie van deze server of website.

TRANSPARANCY

It is crucially import for Amgen to collaborate in the process of discovering, developing, improving and making available innovative therapies that help patients. Our partners in this are care providers, care institutions and patient organizations. We understand the societal importance of us being open and transparent about these collaborations and any corresponding compensation. We report annually on the financial links between Amgen and professionals, institutions and other parties involved in care. With the approval of the collaborating partner, these are published in the Healthcare Transparancy Register.

R&D costs

We are transparent when it comes to our research and development (R&D) costs. Details are published on the website of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
These cover R&D expenditure on clinical trials and trials outside of the clinical environment, inclusive of all related costs. The first reporting period is the 2015 calendar year.

2017 R&D Transfer of value rapport Nederland
2016 R&D Transfer of value rapport Nederland (Update 29/5/2017)
2015 R&D Transfer of value rapport Nederland (Update 28/6/2016)
EFPIA Disclosure Code Methodological Note (English)
Amgen EFPIA Disclosure Code Self-Certification Scheme